Extended Data Fig. 4: Baseline somatic mutation profile of KRAS G12C inhibitor pretreated patients before D3S-001 treatment in Part 2.
From: D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
BOR, best overall response; PD progressive disease; PR, partial response; SD, stable disease.
